<DOC>
	<DOCNO>NCT01606072</DOCNO>
	<brief_summary>The propose study evaluate safety tolerability desmopressin administer perioperatively patient breast cancer undergo surgery first treatment , select optimum dose clinical development product .</brief_summary>
	<brief_title>Perioperative Use Desmopressin ( DDAVP ) Breast Cancer</brief_title>
	<detailed_description>Breast cancer one commonly diagnosed malignancy among woman , mortality relate capacity tumor cell invade produce metastasis . It postulate tumor manipulation surgery result release tumor cell circulation lymphatic system , release cell survive due aggregation among platelet formation fibrin layer embolus . Tumor cell survive transportation circulation join blood vessel invade vascular wall , form metastasis . The interruption process might reduce survival tumor cell thus formation metastasis breast cancer cell lungs tissue .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Deamino Arginine Vasopressin</mesh_term>
	<criteria>. Female subject 21 60 year age , voluntarily sign informed consent form . b. Histological/cytological diagnosis breast carcinoma obtain least 21 day inclusion study . c. Candidate radical mastectomy require resection axillary lymph node sentinel node . d. In case woman childbearing potential , adequate birth control method ( intrauterine device , barrier method , tubal ligation ) use throughout study . Postmenopausal woman menopause confirm biochemical parameter . e. Adequate organic function , define follow parameter : Electrocardiogram ( ECG ) significant anomaly , perform within 14 day prior surgery . The following laboratory result , obtain 7 day surgery : Hemoglobin ≥ 11 g/dL Total white blood cell count ≥ 4,000/mm3 Total neutrophil count 1,500/mm3 Platelet count within normal limit Total bilirubin ≤1.5 x UNL 2.5 x UNL case hepatic metastasis Transaminases ALT/GPT AST/GOT ≤ 1.5 x UNL Creatinine clearance &gt; 50 mg/dL CT scan oral endovenous contrast* chest , pelvis , abdomen , bone scan , conduct within 28 day prior surgery . Images take longer 90 day surgery also acceptable . In case contrast contraindicate , CT contrast MRI perform . f. Subject performance status ( ECOG ) = 0. a. Synchronic bilateral breast cancer . b . Symptoms metastasis evidence metastasis image : chest spiral CT scan , abdomen/pelvis spiral CT scan , brain spiral CT/MRI ( case brain metastasis sign ) , bone scan . c. The patient pregnant breastfeeding . d. The patient presently use hormonal contraceptive hormonal treatment . She would eligible oral contraceptive discontinue hormonal treatment finish 30 day surgery patient agree use another contraceptive method . e. Patients history presence congestive heart failure , blood hypertension , angina pectoris heart arrhythmia , thromboembolic disease , diabetes type I II , underlie coronaropathy detect presurgical evaluation . f. Mentallyimpaired patient . g. Patients know hypersensitivity DDAVP vasopressin , severe von Willebrand 's disease ( VWD ) , define VWF activity &lt; 10 % IU/dL , type 2B VWD , define increase ristocetininduced platelet aggregation ( RIPA ) low concentration ristocetin hemophilia . h. Patients history seizure . . Patients renal impairment ( creatinine clearance &lt; 50 mL/min calculate CockcroftGault formula ) , hyponatremia history hyponatremia . j . Patients syndrome inadequate secretion antidiuretic hormone . k. Patients positive serology hepatitis B C virus and/or HIV . l. Patients know hepatic disease ( diagnosed cirrhosis , hepatic enzyme ( GOT/GPT ) &gt; 1.5 x UNL , Total bilirubin &gt; 1.5 x UNL ) . m. Patients active infection . n. Patients malignant disease , exception , nonmelanoma skin cancer , cervix cancer situ , tumor receive adequate treatment show diseasefree time ≥ 5 year . . Patients participate another clinical study case less 4 week elapse since participation another clinical study .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>DDAVP</keyword>
</DOC>